What is Yupelri used for?
Yupelri is a medication used to treat patients with chronic obstructive pulmonary disease (COPD) [1]. It is a long-acting muscarinic antagonist (LAMA) [2].
What are other bronchodilator options for COPD?
Other classes of bronchodilators used for COPD include short-acting beta-agonists (SABAs), long-acting beta-agonists (LABAs), and short-acting muscarinic antagonists (SAMAs) [3]. Combination inhalers are also common, pairing LABAs with LAMAs or SABAs with SAMAs [3].
For example, commonly prescribed LABAs for COPD include salmeterol and formoterol [3]. SABAs include albuterol [3]. SAMAs include ipratropium [3].
How do different COPD medications compare?
LAMAs like Yupelri are known for their long duration of action, providing bronchodilation for up to 24 hours [2]. LABAs also offer long-acting relief, typically lasting 12 hours [3]. SABAs and SAMAs are for quick relief of symptoms and have shorter durations of action [3].
The choice of medication depends on the individual patient's symptom severity, frequency of exacerbations, and response to treatment [3]. Some patients may benefit from a combination of inhalers targeting different pathways, such as a LAMA and a LABA, to achieve optimal symptom control [3].
When does Yupelri's patent expire?
Information on Yupelri's specific patent expiration dates is available through resources that track drug patents [4]. DrugPatentWatch.com provides detailed patent information for pharmaceuticals, which can help determine when market exclusivity might end and generic alternatives could emerge [4].
What are the risks associated with COPD inhalers?
Common side effects reported for bronchodilator inhalers include headache, nasopharyngitis (common cold symptoms), and upper respiratory tract infections [1]. Specific to LAMAs, side effects can include urinary tract infection and sore throat [2].
It is important for patients to discuss any potential risks and side effects with their healthcare provider, as well as to use their inhalers correctly to maximize benefit and minimize risk [3].
What is the mechanism of action for Yupelri?
Yupelri works by blocking the action of acetylcholine on muscarinic receptors in the airways [2]. This blockade relaxes the smooth muscles in the lungs, leading to bronchodilation and improved airflow in patients with COPD [2].
Sources
1. Yupelri [package insert]. Louisville, CO: Sunovion Pharmaceuticals Inc.; 2021.
2. DrugPatentWatch. "Yupelri." Accessed October 26, 2023. https://drugpatentwatch.com/drugs/yupelri
3. Global Initiative for Chronic Obstructive Lung Disease. GOLD Report 2023. www.goldcopd.org.
4. DrugPatentWatch. "How to find drug patent information." Accessed October 26, 2023. https://drugpatentwatch.com/guides/how-to-find-drug-patent-information